Should Patients Be Allowed to Pay Out of Pocket? The Ethical Dilemma of Access to Expensive Anti-cancer Treatments in Universal Healthcare Systems: A Dutch Case Study.

However, sometimes expected effects might be significant, for instance in the case of new immunotherapies such as Yescarta, a form of CAR-T cell therapy which costs around 400,000 euros per patient and is potentially curative (Hernandez et al. 2018 ).

also in 2,457 other papers